Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
04/2014
04/08/2014US8691238 High growth reassortant influenza A virus
04/08/2014US8691237 Brucella abortus proteins and methods of use thereof
04/08/2014US8691236 Vaccine for a therapeutic or a prophylactic treatment of myasthenia gravis
04/08/2014US8691235 Absorbable crystalline polyether-ester-urethane-based bioactive luminal liner compositions
04/08/2014US8691234 Vaccine formulation potentiated by the combination of DNA and an antigen
04/08/2014US8691233 Antibody molecules having binding specificity for human IL-13
04/08/2014US8691232 Extending time to disease progression or survival in cancer patients
04/08/2014US8691231 Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
04/08/2014US8691230 Methods for inhibiting hematopoiesis with a hedgehog antagonist
04/08/2014US8691228 Stable and soluble antibodies inhibiting TNFα
04/08/2014US8691227 Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
04/08/2014US8691226 Humanized anti-human tumor necrosis factor alpha monoclonal antibody and sequence thereof
04/08/2014US8691225 Antibodies against the ectodomain of ErbB3 and uses thereof
04/08/2014US8691224 Anti-Aβ globulomer 5F7 antibodies
04/08/2014US8691223 Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
04/08/2014US8691222 NLRR-1 antagonists and uses thereof
04/08/2014US8691221 Analgesic treatment with prolonged effect
04/08/2014US8691209 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
04/08/2014CA2693137C Engineered scfv against bovine herpes virus type i
04/08/2014CA2584778C Immunogenic bacterial vesicles with outer membrane proteins
04/08/2014CA2580965C Monoclonal antibodies to progastrin
04/08/2014CA2540703C Methods and compositions for mycoplasma pneumoniae exotoxins
04/08/2014CA2515298C Modified free-living microbes, vaccine compositions and methods of use thereof
04/08/2014CA2480119C Cripto-specific antibodies
04/08/2014CA2447576C Use of hmg fragment as anti-inflammatory agents
04/08/2014CA2380840C Vaccine composition
04/03/2014WO2014052971A1 Immunogenic compositions comprising nanoemulsions
04/03/2014WO2014052931A1 Human toll-like receptor inhibitors and methods of use thereof
04/03/2014WO2014052875A1 Stimulus-sensitive microparticles and methods of use
04/03/2014WO2014052803A2 Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension
04/03/2014WO2014052717A2 Cd20-and egfr-binding proteins enhanced stability
04/03/2014WO2014052713A2 Her2-and vegf-a-binding proteins with enhanced stability
04/03/2014WO2014052672A1 Anti-uroplakin ii antibodies systems and methods
04/03/2014WO2014052621A1 Glycosidase regimen for treatment of infectious disease
04/03/2014WO2014052620A1 Adcc-mediating antibodies, combinations and uses thereof
04/03/2014WO2014052588A1 Attenuated chikungunya virus
04/03/2014WO2014052545A2 Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis
04/03/2014WO2014052490A1 Methods of using fix polypeptides
04/03/2014WO2014052462A2 Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
04/03/2014WO2014052378A2 Subunit immersion vaccines for fish
04/03/2014WO2014052360A2 Glycoprotein preparations
04/03/2014WO2014052188A1 Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
04/03/2014WO2014052064A1 Mesothelin antibodies and methods for eliciting potent antitumor activity
04/03/2014WO2014051412A1 Anti alpha-gal igm monoclonal antibody capable of recognising cells infected with the human papillomavirus, and method for obtaining same
04/03/2014WO2014051111A1 Hepatitis c virus particles formation promoter, and method for producing hepatitis c virus particles
04/03/2014WO2014050779A1 Combination of gsk3 inhibitor and anti-dr5 antibody
04/03/2014WO2014049175A1 Passive immunisation against influenza, in particular h5n1
04/03/2014WO2014049100A1 Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
04/03/2014WO2014049099A1 Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
04/03/2014WO2014049094A1 Recombinant measles virus expressing chikungunya virus polypeptides and their applications
04/03/2014WO2014049087A1 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
04/03/2014WO2014049073A1 Test for hemolytic potential of pharmaceutical products and formulations for risk minimization
04/03/2014WO2014048955A1 Arterivirus
04/03/2014WO2014048921A1 Combinations and uses thereof
04/03/2014WO2014048407A2 Medicinal preparation in the form of antistaphylococcal phage lysate, process of its preparation and use
04/03/2014WO2014047973A1 Monoclonal antibodies specifically recognizing b-raf mutant proteins and preparation method and use thereof
04/03/2014WO2014023952A3 Interleukin-18 inhibitor for use in prevention and treatment of osteoarthritis
04/03/2014WO2014023869A3 Therapeutic use of cd44 inhibitor agents against human acute lymphoblastic leukaemia (all)
04/03/2014WO2014018683A3 A novel method to detect resistance to chemotherapy in patients with lung cancer
04/03/2014WO2014014918A3 X-ding-cd4 peptide
04/03/2014WO2014012007A3 Rspo3 binding agents and uses thereof
04/03/2014WO2014007982A3 C-terminal and central epitope a-beta antibodies
04/03/2014WO2014005683A8 Dna vaccine for use in pancreatic cancer patients
04/03/2014WO2013192594A3 Antigen binding proteins that bind c-met
04/03/2014WO2013191982A3 Antigen binding proteins that bind igf1r
04/03/2014WO2013191591A4 Chimeric protein vaccine against pneumonia caused by streptococcus pneumoniae
04/03/2014WO2013180834A3 Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
04/03/2014WO2013044215A9 Vegf/dll4 binding agents and uses thereof
04/03/2014WO2012078761A3 Dimeric molecular complexes with free cysteine residues and conjugates thereof
04/03/2014WO2012068344A3 Regulation of cathepsin l by its transcription factor dendrin
04/03/2014WO2012065044A3 Treating bladder tumor cells using fibronectin attachment protein as a target
04/03/2014WO2012050892A3 Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors
04/03/2014WO2012037546A3 A broadly protective protein of brucella and its use in brucellosis vaccine preparation
04/03/2014WO2012031046A3 Lipids suitable for liposomal delivery of protein-coding rna
04/03/2014US20140094399 Biodegradable poly(beta-amino esters) and uses thereof
04/03/2014US20140093565 A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof
04/03/2014US20140093540 Immunogenic compositions and expression systems
04/03/2014US20140093538 Method for Priming of T Cells
04/03/2014US20140093537 Immunogenic compositions comprising nanoemulsion and methods of administering the same
04/03/2014US20140093536 Compositions And Methods For Treatment Of Microbial Infections
04/03/2014US20140093535 Combined vaccines for prevention of porcine virus infections
04/03/2014US20140093534 Compositions and methods of enhancing immune responses
04/03/2014US20140093532 Immunogenic Compositions In Particulate Form And Methods For Producing The Same
04/03/2014US20140093530 Malaria vaccines
04/03/2014US20140093527 Compositions and methods for glioblastoma treatment
04/03/2014US20140093525 Compositions and methods of treating opioid addiction
04/03/2014US20140093521 Therapeutic dll4 binding proteins
04/03/2014US20140093519 Methods for pancreatic tissue regeneration
04/03/2014US20140093518 Chemically Programmed Vaccination
04/03/2014US20140093516 Human antibodies that bind the p40 subunit of human il-12/il-23 and uses therefor
04/03/2014US20140093515 Process of afod and afcc and manufacturing and purification processes of proteins
04/03/2014US20140093512 Pharmaceutical formulation comprising an antibody against p-selectin and a sugar selected from sucrose and trehalose
04/03/2014US20140093511 Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
04/03/2014US20140093510 Chlamydia antigens
04/03/2014US20140093507 Diagnostics and Therapeutics for Diseases Associated With G-Protein Coupled Receptor AdipoR2 (AdipoR2)
04/03/2014US20140093502 Immunosuppressive Combination and Its Use in the Treatment or Prophylaxis of Insulin-producing Cell Graft Rejection
04/03/2014US20140093501 Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus
04/03/2014US20140093500 Rsv specific binding molecule
04/03/2014US20140093499 Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
04/03/2014US20140093498 Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
1 ... 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 ... 1823